Lv21
150 积分 2025-05-20 加入
Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
3天前
已完结
Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer
5天前
已完结
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
6天前
已完结
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
10天前
已完结
Neoadjuvant Chemoimmunotherapy for NSCLC
13天前
已完结
Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis
18天前
已完结
Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy
24天前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
24天前
已完结
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
1个月前
已完结
OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial
1个月前
已完结
皖公网安备34019202002308
